Abstract
Background: Amyloid β40 (Aβ40) is the most abundant Aβ peptide in the brain. The cerebrospinal fluid (CSF) level of Aβ40 might therefore be considered to most closely reflect the total Aβ load in the brain. Both in Alzheimers disease (AD) and in normal aging the Aβ load in the brain has a large inter-individual variability. Relating Aβ42 to Aβ40 levels might consequently provide a more valid measure for reflecting the change in Aβ metabolism in dementia patients than the CSF Aβ42 concentrations alone. This measure may also improve differential diagnosis between AD and other dementia syndromes, such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Objective: To investigate the diagnostic value of the CSF Aβ42/Aβ40 ratio in differentiating AD from controls, VaD, DLB and FTD. Methods: We analysed the CSF Aβ42/Aβ40 ratio, phosphorylated tau181 and total tau in 69 patients with AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, and 47 controls. Results: Mean Aβ40 levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, both significantly lower than in AD patients (3698 pg/ml; p < 0.01). Aβ40 levels in AD patients were not significantly different from those in controls (4035 pg/ml; p=0.384). The Aβ42/Aβ40 ratio was significantly lower in AD patients than in all other groups (p < 0.001, ANCOVA). Differentiating AD from VaD, DLB and non-AD dementia improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 concentrations alone (p < 0.01) The Aβ42/Aβ40 ratio performed equally well as the combination of Aβ42, phosphorylated tau181 and total tau in differentiating AD from FTD and non-AD dementia. The diagnostic performance of the latter combination was not improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 alone. Conclusion: The CSF Aβ42/Aβ40 ratio improves differentiation of AD patients from VaD, DLB and non-AD dementia patients, when compared to Aβ42 alone, and is a more easily interpretable alternative to the combination of Aβ42, p-tau and t-tau when differentiating AD from either FTD or non-AD dementia.
Keywords: Abeta40 protein, Aβ42/Aβ40 ratio, Alzheimer's disease, vascular dementia, dementia with Lewy bodies
Current Alzheimer Research
Title: The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia
Volume: 7 Issue: 5
Author(s): P.E. Spies, D. Slats, J.M.C. Sjogren, B.P.H. Kremer, F.R.J. Verhey, M.G.M. Olde Rikkert and M.M. Verbeek
Affiliation:
Keywords: Abeta40 protein, Aβ42/Aβ40 ratio, Alzheimer's disease, vascular dementia, dementia with Lewy bodies
Abstract: Background: Amyloid β40 (Aβ40) is the most abundant Aβ peptide in the brain. The cerebrospinal fluid (CSF) level of Aβ40 might therefore be considered to most closely reflect the total Aβ load in the brain. Both in Alzheimers disease (AD) and in normal aging the Aβ load in the brain has a large inter-individual variability. Relating Aβ42 to Aβ40 levels might consequently provide a more valid measure for reflecting the change in Aβ metabolism in dementia patients than the CSF Aβ42 concentrations alone. This measure may also improve differential diagnosis between AD and other dementia syndromes, such as vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Objective: To investigate the diagnostic value of the CSF Aβ42/Aβ40 ratio in differentiating AD from controls, VaD, DLB and FTD. Methods: We analysed the CSF Aβ42/Aβ40 ratio, phosphorylated tau181 and total tau in 69 patients with AD, 26 patients with VaD, 16 patients with DLB, 27 patients with FTD, and 47 controls. Results: Mean Aβ40 levels were 2850 pg/ml in VaD and 2830 pg/ml in DLB patients, both significantly lower than in AD patients (3698 pg/ml; p < 0.01). Aβ40 levels in AD patients were not significantly different from those in controls (4035 pg/ml; p=0.384). The Aβ42/Aβ40 ratio was significantly lower in AD patients than in all other groups (p < 0.001, ANCOVA). Differentiating AD from VaD, DLB and non-AD dementia improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 concentrations alone (p < 0.01) The Aβ42/Aβ40 ratio performed equally well as the combination of Aβ42, phosphorylated tau181 and total tau in differentiating AD from FTD and non-AD dementia. The diagnostic performance of the latter combination was not improved when the Aβ42/Aβ40 ratio was used instead of Aβ42 alone. Conclusion: The CSF Aβ42/Aβ40 ratio improves differentiation of AD patients from VaD, DLB and non-AD dementia patients, when compared to Aβ42 alone, and is a more easily interpretable alternative to the combination of Aβ42, p-tau and t-tau when differentiating AD from either FTD or non-AD dementia.
Export Options
About this article
Cite this article as:
Spies P.E., Slats D., Sjogren J.M.C., Kremer B.P.H., Verhey F.R.J., Olde Rikkert M.G.M. and Verbeek M.M., The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia, Current Alzheimer Research 2010; 7 (5) . https://dx.doi.org/10.2174/156720510791383796
DOI https://dx.doi.org/10.2174/156720510791383796 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Many Faces of Amyloid β in Alzheimers Disease
Current Molecular Medicine Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia
Current Psychiatry Reviews The Molecular and Pharmacological Mechanisms of HIV-Related Neuropathic Pain
Current Neuropharmacology Human Cognition Assessment in Drug Research
Current Pharmaceutical Design Effect of Red Wine Polyphenols on the Expression of Transthyretin in Murine Choroid Plexus
Current Pharmaceutical Biotechnology Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design The Many Roles of Chemokine Receptors in Neurodegenerative Disorders: Emerging New Therapeutical Strategies
Current Medicinal Chemistry Olfactory Dysfunction and Cognitive Impairment in Age-Related Neurodegeneration: Prevalence Related to Patient Selection, Diagnostic Criteria and Therapeutic Treatment of Aged Clients Receiving Clinical Neurology and Community-Based Care
Current Clinical Pharmacology Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Lesions and Dysfunctions of the Nucleus Basalis as Alzheimers Disease Models: General and Critical Overview and Analysis of the Long-Term Changes in Several Excitotoxic Models
Current Alzheimer Research Structure-Function Implications in Alzheimers Disease: Effect of Aβ Oligomers at Central Synapses
Current Alzheimer Research Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise
Current Pharmaceutical Design Herbal Medicine for Anxiety, Depression and Insomnia
Current Neuropharmacology Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Computational Models of Neuronal Biophysics and the Characterization of Potential Neuropharmacological Targets
Current Medicinal Chemistry Microwave Assisted One-pot Three Component Synthesis of Novel 2-(5- Aryloxymethyl-1,3,4-thiadiazolo)-3-aryl-4-thiazolidinones
Letters in Organic Chemistry Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognitive Impairment
Current Alzheimer Research A Resurrection of 7-MEOTA: A Comparison with Tacrine
Current Alzheimer Research Using Non-Pharmacological Approaches for CJD Patient and Family Support as Provided by the CJD Foundation and CJD Insight
CNS & Neurological Disorders - Drug Targets Does Intraneuronal Accumulation of Carboxyl-terminal Fragments of the Amyloid Precursor Protein Trigger Early Neurotoxicity in Alzheimer’s Disease?
Current Alzheimer Research